Ipsen Collaborates with Day One Biopharmaceuticals for the commercialization of Tovorafenib to Treat Pediatric Low-Grade Glioma
Shots:
- Ipsen and Day One Biopharmaceuticals have entered into an exclusive ex-US licensing agreement for the commercialization of tovorafenib (oral, QW, type II RAF inhibitor) to treat pediatric low-grade glioma (pLGG) and other indications developed by Day One
- As per the agreement, Ipsen will be responsible for regulatory & commercial activities outside the US while Day One will retain exclusive worldwide development plus the US commercialization rights for tovorafenib
- Furthermore, Day One is entitled to receive ~$111M upfront (~$71M cash + $40M equity), ~$350M additional launch and sales milestones plus double-digit tiered royalties starting at mid-teens percentage
Ref: Ipsen | Image: Ipsen
Related News:- Ipsen Teams Up with Foreseen Biotechnology to Develop FS001 for Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
